...
search icon
supn-img

Supernus Pharmaceuticals Inc, Common Stock

SUPN

NMQ

$31.67

+$0.6

(1.93%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.77B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
24.0853
Volume info-icon
This is the total number of shares traded during the most recent trading day.
407.13K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.90
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$25.53 L
$40.28 H
$31.67

About Supernus Pharmaceuticals Inc, Common Stock

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameSUPNSectorS&P500
1-Week Return-3.27%-0.29%3.55%
1-Month Return-1.09%-7.65%-5.72%
3-Month Return-15.7%-4.64%-9.82%
6-Month Return-4.03%-12.35%-9.51%
1-Year Return-1.03%-4.34%1.26%
3-Year Return-0.53%-3.64%19.2%
5-Year Return69.27%43.5%90.39%
10-Year Return142.31%83.13%151.51%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue520.40M579.77M667.24M607.52M661.82M[{"date":"2020-12-31","value":77.99,"profit":true},{"date":"2021-12-31","value":86.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.05,"profit":true},{"date":"2024-12-31","value":99.19,"profit":true}]
Cost of Revenue52.46M75.06M87.22M83.78M77.91M[{"date":"2020-12-31","value":60.14,"profit":true},{"date":"2021-12-31","value":86.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.05,"profit":true},{"date":"2024-12-31","value":89.32,"profit":true}]
Gross Profit467.94M504.71M580.02M523.74M583.91M[{"date":"2020-12-31","value":80.14,"profit":true},{"date":"2021-12-31","value":86.44,"profit":true},{"date":"2022-12-31","value":99.33,"profit":true},{"date":"2023-12-31","value":89.7,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin89.92%87.05%86.93%86.21%88.23%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.81,"profit":true},{"date":"2022-12-31","value":96.67,"profit":true},{"date":"2023-12-31","value":95.87,"profit":true},{"date":"2024-12-31","value":98.12,"profit":true}]
Operating Expenses292.34M425.21M534.40M529.01M502.25M[{"date":"2020-12-31","value":54.7,"profit":true},{"date":"2021-12-31","value":79.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.99,"profit":true},{"date":"2024-12-31","value":93.98,"profit":true}]
Operating Income173.70M86.03M67.30M(5.27M)81.67M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":49.53,"profit":true},{"date":"2022-12-31","value":38.75,"profit":true},{"date":"2023-12-31","value":-3.03,"profit":false},{"date":"2024-12-31","value":47.02,"profit":true}]
Total Non-Operating Income/Expense(10.10M)(25.71M)29.24M14.90M32.41M[{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":-79.33,"profit":false},{"date":"2022-12-31","value":90.22,"profit":true},{"date":"2023-12-31","value":45.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income168.65M73.17M60.74M2.77M97.87M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.39,"profit":true},{"date":"2022-12-31","value":36.02,"profit":true},{"date":"2023-12-31","value":1.64,"profit":true},{"date":"2024-12-31","value":58.03,"profit":true}]
Income Taxes41.70M19.75M32.00K1.45M24.00M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":47.37,"profit":true},{"date":"2022-12-31","value":0.08,"profit":true},{"date":"2023-12-31","value":3.48,"profit":true},{"date":"2024-12-31","value":57.57,"profit":true}]
Income After Taxes126.95M53.42M60.71M1.32M73.86M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true},{"date":"2024-12-31","value":58.18,"profit":true}]
Income From Continuous Operations126.95M53.42M60.71M25.62M73.86M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":20.18,"profit":true},{"date":"2024-12-31","value":58.18,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income126.95M53.42M60.71M1.32M73.86M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":47.82,"profit":true},{"date":"2023-12-31","value":1.04,"profit":true},{"date":"2024-12-31","value":58.18,"profit":true}]
EPS (Diluted)2.360.981.031.401.86[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":41.53,"profit":true},{"date":"2022-12-31","value":43.64,"profit":true},{"date":"2023-12-31","value":59.32,"profit":true},{"date":"2024-12-31","value":78.74,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SUPN
Cash Ratio 1.55
Current Ratio 2.35
Quick Ratio 2.16

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SUPN
ROA (LTM) 2.90%
ROE (LTM) 7.55%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SUPN
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SUPN
Trailing PE 23.99
Forward PE 20.16
P/S (TTM) 2.67
P/B 1.71
Price/FCF 40
EV/R 2.04
EV/Ebitda 7.56
PEG 1.47

FAQs

What is Supernus Pharmaceuticals Inc share price today?

Supernus Pharmaceuticals Inc (SUPN) share price today is $31.67

Can Indians buy Supernus Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Supernus Pharmaceuticals Inc (SUPN) on Vested. To buy Supernus Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SUPN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Supernus Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Supernus Pharmaceuticals Inc (SUPN) via the Vested app. You can start investing in Supernus Pharmaceuticals Inc (SUPN) with a minimum investment of $1.

How to invest in Supernus Pharmaceuticals Inc shares from India?

You can invest in shares of Supernus Pharmaceuticals Inc (SUPN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SUPN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Supernus Pharmaceuticals Inc shares
What is Supernus Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Supernus Pharmaceuticals Inc (SUPN) is $40.28. The 52-week low price of Supernus Pharmaceuticals Inc (SUPN) is $25.53.

What is Supernus Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Supernus Pharmaceuticals Inc (SUPN) is 24.0853

What is Supernus Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Supernus Pharmaceuticals Inc (SUPN) is 1.71

What is the Market Cap of Supernus Pharmaceuticals Inc?

The market capitalization of Supernus Pharmaceuticals Inc (SUPN) is $1.77B

What is Supernus Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Supernus Pharmaceuticals Inc is SUPN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top